Juvenile Arthritis
FDA approves high-concentration, citrate-free form of interchangeable biosimilar Cyltezo
The FDA has approved a citrate-free, high-concentration formulation of the interchangeable adalimumab biosimilar Cyltezo to treat multiple chronic inflammatory diseases, according to the manufacturer.
FDA authorizes first CAR T-cell trial for children with lupus
The FDA has authorized the first chimeric antigen receptor T-cell clinical trial for children with systemic lupus erythematosus.
Peripheral apoptotic lymphocytes may predict disease activity in juvenile-onset lupus
Apoptotic lymphocytes in peripheral blood may be a meaningful factor in the prognosis of juvenile-onset systemic lupus erythematosus, as well as a predictor of disease activity, according to data published in Pediatric Rheumatology.
Celltrion submits application for Actemra biosimilar to FDA
Celltrion USA has submitted a Biologics License Application to the FDA for its tocilizumab biosimilar candidate CT-P47, according to a press release.
Match Day fills 61.5% of pediatric rheumatology fellowship slots, continuing decline
Pediatric rheumatology fellowship programs filled just 61.5% of available slots for 2024 in the National Resident Matching Program, while nearly all adult program slots were filled, according to the American College of Rheumatology.
FDA expands approval of abatacept for children with psoriatic arthritis
The FDA has approved a supplemental biologics licensing application from Bristol Myers Squibb expanding the indication of abatacept to include children aged 2 years and older with psoriatic arthritis, according to a company press release.
Juvenile arthritis prevalence increases with age, depression, food insecurity
Approximately 220,000 children in the United States were diagnosed with arthritis between 2017 and 2021, with a higher prevalence among those aged 12 to 17 years or living in a food-insecure household, according to data.
Infant microbiome dysregulation predicts juvenile idiopathic arthritis development
Infants who demonstrate microbiome dysregulation may be at a higher risk for juvenile idiopathic arthritis, according to data published in eBioMedicine.
TEACH combines meditation, education to manage fatigue, pain in childhood-onset lupus
A program using cognitive behavioral and mindfulness meditation techniques demonstrated early potential to ease fatigue, depression and pain symptoms in childhood-onset systemic lupus erythematosus, according to researchers.
Multiple recent FDA approvals in pediatric rheumatology overcome ‘delayed’ trials
SAN DIEGO — The recent approvals of belimumab, golimumab, tofacitinib, secukinumab and ustekinumab in children with rheumatic diseases, all within the past 4 years, have changed the landscape in pediatric rheumatology, noted a speaker here.